Liquid Biopsy Market Report (10th Edition): 2027-2031 Forecast, Technology and Partnering Opportunities by Cancer Type, Application, Analyte, Technology Platform, Product and Country - Strategic Analysis of 90 Companies

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2.1 Forecast Approach
2.2 Data Sources
2.3 Scope & Definitions
2.4 Limitations
2.5 Authors

3.1 What is Liquid Biopsy?
3.2 The Sequencing Revolution
3.3 Tissue Biopsy Today
3.4 The Situation Today - Biopsy Analysis
3.5 Liquid Biopsy Analytes
3.6 The Promise of Liquid Biopsy

4.1 Global Market Overview by Country
4.2 Global Market by Cancer Type - Overview
4.3 Global Market by Application - Overview
4.4 Global Market by Analyte - Overview
4.5 Global Market by Technology Platform - Overview
4.6 Global Market by Product - Overview

5.1 FDA-Approved Liquid Biopsy Tests
5.2 Leading Laboratory-Developed Tests
5.3 Commercial Benchmarking
5.4 Clinical Applications by Analyte

6.1 Pipeline Overview
6.2 Landmark Clinical Studies
6.3 Phases of Adoption
6.4 The Screening Opportunity
6.5 Cancer Management vs. Diagnosis

7.1 CTC Detection Platforms
7.2 Circulating Tumour DNA Methods
7.3 Next-Generation Sequencing
7.4 Instrumentation and Automation
7.5 Artificial Intelligence
7.6 Other Emerging Technologies

8.1 Liquid Biopsy Companion Diagnostics
8.2 Pharma Partnerships
8.3 Commercial and Biological Rationale

9.1 United States: FDA and Laboratory-Developed Tests
9.2 Europe, China and Other Markets
9.3 Reimbursement
9.4 Laboratory Accreditation

10.1 Patent Landscape
10.2 Litigation
10.3 Price Erosion

11.1 Market Overview
11.2 Key Companies
11.3 Sequencing Supply and Trade Tensions
11.4 Why China Matters to Global Companies

12.1 Deal Database
12.2 Deal Themes
12.3 Valuation Trends

13.1 Recent Developments - Importance and How to Use This Section
13.2 FDA Advisory Panel Backs GRAIL's Galleri Multi-Cancer Early Detection Test
13.3 FDA Approves Freenome's SimpleScreen CRC Blood Test; Abbott to Commercialize
13.4 Tempus AI to Acquire Personalis for $1.5 Billion
13.5 FDA Approves the New Guardant360 Liquid CDx, the Largest Approved Liquid Biopsy Panel
13.6 Signatera CDx Becomes the First FDA-Approved MRD Companion Diagnostic
13.7 Roche to Acquire SAGA Diagnostics for up to $595 Million
13.8 CareDx to Acquire Naveris for up to $260 Million
13.9 Medicare Coverage Law for Multi-Cancer Early Detection Tests Signed
13.10 NHS-Galleri Results: Fewer Stage IV Cancers, but Primary Endpoint Missed
13.11 Natera Acquires Foresight Diagnostics for up to $450 Million

14.1 Central Laboratories vs. Hospital Laboratories
14.2 Decentralisation
14.3 Physician Offices and Point of Care
14.4 Sequencing and Reagent Supply
14.5 Capacity and Turnaround

15.1 Market Structure
15.2 Healthcare and the IVD Industry
15.3 Leading Companies
15.4 Emerging and China-Based Players
15.5 Outlook

16.1 Factors Driving Growth
16.2 Factors Limiting Growth
16.3 SWOT Analysis
16.4 Porter's Five Forces
16.5 Key Investment Risks

17.1 Guidance for Executives, Marketing, Sales and Business Development
17.2 White-Space Opportunities
17.3 Partnering Strategy Guidance

18.1 Lung
18.2 Breast
18.3 Colorectal
18.4 Prostate
18.5 HPV-Associated
18.6 Multi-Cancer
18.7 Other Cancer

19.1 Single-Cancer Screening
19.2 Multi-Cancer Screening
19.3 Diagnosis & Triage
19.4 Therapy Selection / CDx
19.5 MRD & Monitoring

20.1 ctDNA - Genomic
20.2 cfDNA - Epigenomic
20.3 CTC
20.4 Exosomes / EVs
20.5 Other Analyte

21.1 NGS
21.2 PCR & Digital PCR
21.3 Other Platform

22.1 Central Lab Services
22.2 Kits & Reagents
22.3 Instruments

23.1 Abbott Laboratories
23.2 AccuraGen
23.3 AcuamarkDx
23.4 Admera Health
23.5 Agilent Technologies
23.6 Amoy Diagnostics (AmoyDx)
23.7 AnchorDx (Kindstar Globalgene)
23.8 ANGLE plc
23.9 ARUP Laboratories
23.10 Beckman Coulter (Danaher)
23.11 Becton, Dickinson and Company (BD)
23.12 BGI Genomics
23.13 BillionToOne
23.14 Bioarray Genetics
23.15 Biocartis
23.16 Biodesix
23.17 BioFluidica
23.18 Biolidics
23.19 bioMérieux
23.20 Bioneer
23.21 Bio-Rad Laboratories
23.22 Bio-Techne
23.23 BioView
23.24 Burning Rock Biotech
23.25 CareDx
23.26 Caris Life Sciences
23.27 CellCarta
23.28 CellMax Life
23.29 Cepheid (Danaher)
23.30 Circulogene
23.31 Cizzle Biotechnology
23.32 Clinical Genomics
23.33 Datar Cancer Genetics
23.34 Delfi Diagnostics
23.35 Dxcover
23.36 Element Biosciences
23.37 Epic Sciences
23.38 Eurofins Scientific
23.39 Exact Sciences (Abbott)
23.40 Fluxion Biosciences
23.41 Foundation Medicine (Roche)
23.42 Freenome
23.43 FYR Diagnostics (FYR Bio)
23.44 GeneFirst
23.45 Genetron Health
23.46 GRAIL
23.47 Guardant Health
23.48 HansaBioMed Life Sciences (Lonza)
23.49 Harbinger Health
23.50 HLB Panagene
23.51 iCellate Medical
23.52 Illumina
23.53 INOVIQ
23.54 Johnson & Johnson Innovative Medicine
23.55 Labcorp
23.56 Lucence
23.57 MDxHealth
23.58 Menarini Silicon Biosystems
23.59 MilliporeSigma (Merck KGaA)
23.60 Miltenyi Biotec
23.61 miR Scientific
23.62 Mirxes
23.63 Myriad Genetics
23.64 Natera
23.65 NeoGenomics
23.66 Novogene
23.67 On-Chip Biotechnologies
23.68 Oncocyte
23.69 OncoDNA
23.70 Oxford Nanopore Technologies
23.71 Personalis (Tempus AI)
23.72 Predicine
23.73 Promega
23.74 Qiagen
23.75 Quest Diagnostics
23.76 Rarecells Diagnostics
23.77 RareCyte
23.78 Revvity
23.79 Roche Diagnostics
23.80 SAGA Diagnostics (Roche)
23.81 ScreenCell
23.82 Siemens Healthineers
23.83 Singlera Genomics
23.84 Standard BioTools
23.85 Sysmex (Sysmex Inostics)
23.86 Tempus AI
23.87 Thermo Fisher Scientific
23.88 Ultima Genomics
23.89 Veracyte
23.90 VolitionRx

24.1 Abbreviations
24.2 Report Limitations Restated
24.3 Developments Archive
24.4 IVD Test Menu and Fee Data

Table 1 Leading Liquid Biopsy Tests
Table 2 Biopsy Sites
Table 3 Global Market by Country
Table 4 Global Market by Cancer Type
Table 5 Global Market by Application
Table 6 Global Market by Analyte
Table 7 Global Market by Technology Platform
Table 8 Global Market by Product
Table 9 FDA-Approved and Cleared Liquid Biopsy Tests
Table 10 Leading Laboratory-Developed Liquid Biopsy Tests
Table 11 Commercial Benchmarking of Leading Companies
Table 12 LB Clinical Applications by Entity
Table 13 Landmark Liquid Biopsy Studies
Table 14 Outlook - Phases of Liquid Biopsy Adoption by Year
Table 15 Advantages of Liquid Biopsy in Screening Market
Table 16 Next Generation Sequencing Technologies - Speed and Cost
Table 17 Selected FDA-Approved Liquid Biopsy Companion Diagnostics
Table 18 Selected Liquid Biopsy Litigation
Table 19 Selected Chinese Liquid Biopsy Companies
Table 20 Liquid Biopsy Deal Database
Table 21 Market Players by Type
Table 22 Five Factors Driving Growth
Table 23 Factors Limiting Growth
Table 24 SWOT Analysis - Internal Factors
Table 25 SWOT Analysis - External Factors
Table 26 Lung by Country
Table 27 Breast by Country
Table 28 Colorectal by Country
Table 29 Prostate by Country
Table 30 HPV-Associated by Country
Table 31 Multi-Cancer by Country
Table 32 Other Cancer by Country
Table 33 Single-Cancer Screening by Country
Table 34 Multi-Cancer Screening by Country
Table 35 Diagnosis & Triage by Country
Table 36 Therapy Selection / CDx by Country
Table 37 MRD & Monitoring by Country
Table 38 ctDNA - Genomic by Country
Table 39 cfDNA - Epigenomic by Country
Table 40 CTC by Country
Table 41 Exosomes / EVs by Country
Table 42 Other Analyte by Country
Table 43 NGS by Country
Table 44 PCR & Digital PCR by Country
Table 45 Other Platform by Country
Table 46 Central Lab Services by Country
Table 47 Kits & Reagents by Country
Table 48 Instruments by Country
Table 49 The Most Common Assays
Table 50 Largest Revenue Assays
Table 51 Clinical Lab Fee Schedule

Figure 1 Key Graphic - Where the Growth Is: Liquid Biopsy Market by Application, 2026 vs 2031
Figure 2 Comparison of Liquid vs Tissue Biopsy
Figure 3 Entities Analyzed in liquid Biopsy
Figure 4 Characteristics of Different Vesicle Types
Figure 5 Global Market Pareto Chart
Figure 6 Global Market by Cancer Type - Base vs. Final
Figure 7 Global Market by Cancer Type Base Year
Figure 8 Global Market by Cancer Type End Year
Figure 9 Cancer Type Share by Year
Figure 10 Cancer Type Segments Growth
Figure 11 Global Market by Application - Base vs. Final
Figure 12 Global Market by Application Base Year
Figure 13 Global Market by Application End Year
Figure 14 Application Share by Year
Figure 15 Application Segments Growth
Figure 16 Global Market by Analyte - Base vs. Final
Figure 17 Global Market by Analyte Base Year
Figure 18 Global Market by Analyte End Year
Figure 19 Analyte Share by Year
Figure 20 Analyte Segments Growth
Figure 21 Global Market by Technology Platform - Base vs. Final
Figure 22 Global Market by Technology Platform Base Year
Figure 23 Global Market by Technology Platform End Year
Figure 24 Technology Platform Share by Year
Figure 25 Technology Platform Segments Growth
Figure 26 Global Market by Product - Base vs. Final
Figure 27 Global Market by Product Base Year
Figure 28 Global Market by Product End Year
Figure 29 Product Share by Year
Figure 30 Product Segments Growth
Figure 31 Global Healthcare Spending Picture
Figure 32 The Global Lab Test Pie
Figure 33 The Changing Age of World Population
Figure 34 Health Care Consumption by Age
Figure 35 Cancer Incidence - Age at Diagnosis
Figure 36 Lung Growth
Figure 37 Breast Growth
Figure 38 Colorectal Growth
Figure 39 Prostate Growth
Figure 40 HPV-Associated Growth
Figure 41 Multi-Cancer Growth
Figure 42 Other Cancer Growth
Figure 43 Single-Cancer Screening Growth
Figure 44 Multi-Cancer Screening Growth
Figure 45 Diagnosis & Triage Growth
Figure 46 Therapy Selection / CDx Growth
Figure 47 MRD & Monitoring Growth
Figure 48 ctDNA - Genomic Growth
Figure 49 cfDNA - Epigenomic Growth
Figure 50 CTC Growth
Figure 51 Exosomes / EVs Growth
Figure 52 Other Analyte Growth
Figure 53 NGS Growth
Figure 54 PCR & Digital PCR Growth
Figure 55 Other Platform Growth
Figure 56 Central Lab Services Growth
Figure 57 Kits & Reagents Growth
Figure 58 Instruments Growth
Figure 59 IVD Test Menu Growth
Figure 60 IVD Test Average Fees - A Ten Year View